Content area


Flibanserin som farmakologisk behandling af nedsat lyst hos kvinder

Anne Sofie Eldon1 & Annamaria Giraldi2, 3 1) Sundhedsvidenskabeligt Fakultet, Københavns Universitet 2) Sexologisk Klinik, Psykiatrisk Center København 3) Institut for Klinisk Medicin, Københavns Universitet Ugeskr Læger 2017;179:V03160209
Ugeskr Læger 2017;179:V03160209
Blad nummer: 
Flibanserin as pharmacological therapy of inhibited sexual desire in women
Flibanserin was approved by the Food and Drug Administration in the USA in August 2015 as the first drug for the treatment of American women with the dysfunction hypoactive sexual desire disorder (HSDD) and is a 5-HT1A agonist and 5-HT2A antagonist. The neurophysiological effects of flibanserin on these receptors are consistent with the clinical effects, i.e. significantly increasing sexual desire and frequency of satisfying sexual experiences. As such, shifting the balance between inhibitory and excitatory neurotransmitters of importance to sexual desire, flibanserin pharmacologically broaches a possible new approach to the treatment of HSDD.
Du skal være logget ind for at læse denne artikel
Log ind

Right side